Annual Meeting 2013 Educational Session

The Diagnosis, Classification, and Clinical Care of Myelodysplastic Syndromes (DC3-MDS)
Held on September 20, 2013 at 3:15 PM

The American Society for Clinical Pathology (ASCP) designates this enduring material for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In addition, this activity meets requirements for the American Board of Pathology’s (ABP) Maintenance of Certification (MOC) Part II (SAMs/AMA PRA Category 1 Credit(s)™).

Download slides from session >>

Download references >>

Check back here for educational materials adapted from the Annual Meeting DC3-MDS Educational Session.

Educational Session Faculty

Maria R. Baer, MD
Professor of Medicine
University of Maryland School of Medicine
Director, Hematologic Malignancies
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland

Magdalena Czader, MD, PhD
Associate Professor of Pathology
Director, Division of Hematopathology
Department of Pathology and Laboratory Medicine
Indiana University School of Medicine
Indianapolis, Indiana

Charles Goolsby, PhD
Floyd Elroy Patterson Research Professor of Pathology
Department of Pathology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Michelle M. Le Beau, PhD
Arthur and Marian Edelstein Professor of Medicine
Director, University of Chicago
Comprehensive Cancer Center
Chicago, Illinois

Kaaren Reichard, MD
Associate Professor of Pathology
Division of Hematopathology
Mayo Clinic
Rochester, Minnesota

Mikkael A. Sekeres, MD, MS
Professor of Medicine
Vice-Chair for Clinical Research
Director, Leukemia Program
Taussig Cancer Institute
Cleveland, Ohio


Learning Objectives:
Upon completion of the educational interventions, participants will be able to:

  1. Recognize the indications for using certain tests when considering a diagnosis of MDS.
  2. Recognize the morphological and flow cytometry  features of MDS
  3. Apply the 2008 World Health Organization (WHO) MDS classification system for diagnosis.
  4. Recognize the importance of cytogenetic and molecular evaluation in MDS, the methods used, and their application.
  5. Develop a comprehensive report based on morphological, clinical, flow cytometry and cytogenetic findings.
  6. Describe MDS prognostic scoring systems and know how to apply them.
  7. Apply best practices in communications between the pathologists and referring clinician to ensure optimal diagnosis and treatment for patients with MDS.

A comprehensive case based discussion of the clinical approach, diagnosis, classification and clinical care of MDS by the MDS clinical care team including oncologists, hematopathologists, flow cytometrists and cytogenetist/molecular geneticists. Case(s) will include a description and explanation of the latest guidelines from the 2008 WHO MDS classification, the international prognostic scoring system (IPSS) for MDS, the role of flow cytometry including granulocytic and monocytic maturation patterns, conventional cytogenetics, clinical applications of FISH, SNP/CGH and next generation sequencing. The session will conclude with a round table discussion addressing best MDS interdisciplinary team practices.